Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

S&P TSX Capped Composite...

US Dollar vs CAD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Immuneering (NASDAQ:IMRX)
Historical Stock Chart
From Feb 2025 to Mar 2025

Click Here for more Immuneering Charts.

Immuneering (NASDAQ:IMRX)
Historical Stock Chart
From Mar 2024 to Mar 2025

Click Here for more Immuneering Charts.

Immuneering Corporation News

Form 4 - Statement of changes in beneficial ownership of securities
Friday 7 February 2025 (1 month ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 7 February 2025 (1 month ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 7 February 2025 (1 month ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 7 February 2025 (1 month ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 7 February 2025 (1 month ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 7 February 2025 (1 month ago) • Edgar (US Regulatory)

Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)
Thursday 6 February 2025 (1 month ago) • GlobeNewswire Inc.

Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Monday 3 February 2025 (1 month ago) • GlobeNewswire Inc.

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Friday 17 January 2025 (2 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Monday 13 January 2025 (2 months ago) • Edgar (US Regulatory)

Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer
Monday 13 January 2025 (2 months ago) • GlobeNewswire Inc.

Form 8-K - Current report
Tuesday 7 January 2025 (2 months ago) • Edgar (US Regulatory)

More Immuneering Corporation News Articles

TheGlobe com (PK)

FuelCell Energy

Halozyme Therapeutics

Digital Brand Media and ... (PK)

Adia Nutrition (PK)

North Bay Resources (PK)

NioCorp Developments

Lightwave Logic

Rennova Health (CE)

Fannie Mae (QB)

MineralRite (PK)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions